Evaluating the role of human papillomaviruses in conjunctival neoplasia by Tornesello, M L et al.
Short Communication
Evaluating the role of human papillomaviruses in conjunctival
neoplasia
ML Tornesello
1, ML Duraturo
1, KM Waddell
2, B Biryahwaho
3, R Downing
3, S Balinandi
3, SB Lucas
4,
L Buonaguro
1 and FM Buonaguro*,1
1Viral Oncology and AIDS Reference Centre, National Cancer Institute ‘Fond. Pascale’, Cappella Cangiani, I-80131 Naples, Italy;
2Uganda Eye Project,
PO Box 4008, Kampala, Uganda;
3Uganda Virus Research Institute, PO Box 49, Entebbe, Uganda;
4Department of Histopathology, Guy’s, King’s &
St Thomas’ School of Medicine, St Thomas’ Hospital, London SE1, UK
Mucosal, cutaneous and Epidermodysplasia verruciformis (EV)-related human papillomaviruses (HPVs) were searched by broad-
spectrum PCR in 86 conjunctival neoplasia biopsies and 63 conjunctival non-neoplastic control tissue from Ugandan subjects. Seven
different EV-related HPV types, including a putative new HPV, and two mucosal HPVs were detected in 25% (14 out of 56) of HIV-
positive, in 10% (three out of 30) of HIV-negative conjunctival neoplasia samples, and rarely (0–1.6%) in control subjects. The
absence of high-risk HPVs and the low detection frequency of EV-related HPV types in more advanced tumour stages (10%) raise
doubts about their role in conjunctival carcinomas.
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Conjunctival squamous cell neoplasia embraces ocular surface
epithelial premalignant dysplasias and invasive carcinoma (Blodi,
1973). The histological staging is classified, as in cervical
squamous cell neoplasia, by the thickness of epithelial dysplastic
changes and the tumour invasion into the substantia propria
(Waring et al, 1984). Although rare in Europe and USA,
conjunctival neoplasia has been reported to be relatively common
in regions of sub-Saharan Africa since the 1960s (Templeton,
1973). An emerging miniepidemic of conjunctival tumours has
been described in Rwanda, Uganda and Tanzania in association
with the epidemic of HIV infection since the 1980s (Ateenyi-
Agaba, 1995; Waddell et al, 1996; Newton et al, 2002). The spread
of HIV in Uganda, indeed, probably accounts for much of the
approximately eight-fold increase in the incidence of conjunctival
carcinoma observed during the last 20 years (Wabinga et al, 2000).
So far the aetiology of conjunctival neoplasia is not adequately
understood, although the association with HIV infection is most
likely mediated by the immunosuppression, as in the other HIV-
associated cancers (Beral and Newton, 1998).
High-risk mucosal human papillomavirus (HPV) types 16 and
18 have been detected in tissue biopsies of conjunctival neoplasias,
although with highly variable results (Waddell et al, 1996;
Buonaguro et al, 2000; Eng et al, 2002; Moubayed et al, 2004).
More recently, Ateenyi-Agaba et al (2004) reported the presence of
a discrete number of Epidermodysplasia verruciformis (EV) HPV
types in 86% of invasive conjunctival squamous cell carcinoma, of
which HIV serology was unknown, strongly suggesting their
possible role also in such tumours.
We have analysed conjunctival neoplasia biopsies at different
stages of malignancy (from conjunctival intraepithelial lesions
grade 1 (CIN1) to invasive conjunctival squamous cell carcinoma
(ICSCC)) to determine the prevalence of mucosal, cutaneous as
well as EV-related HPV types in such lesions and their association
with the tumour progression in HIV-positive as well as HIV-
negative patients.
PATIENTS AND METHODS
In total, 125 consecutive patients clinically diagnosed with
conjunctival neoplasia at seven countrywide eye clinics in South-
ern Uganda, as part of the Ugandan Ruharo Eye Project, were
enrolled as cases for this study between January 1997 and March
1999. The 125 cancer-free controls, frequency matched to the cases
by sex and age (710 years), were consecutively randomly enrolled
from a pool of patients treated for benign eye lesions (i.e.,
pterygium) or eye injuries, within the same period of time, in the
same eye clinics. All enrolled subjects, representing more than
95% of those approached, agreed to provide informed consent
to participate. Blood serum samples were prospectively obtained
from all cases (patients) as well as control subjects and analysed
for HIV serology (ELISA screening followed by Western blot
confirmation). The histological evaluation confirmed a total
of 118 case biopsies as conjunctival neoplasias, the remaining
seven were not confirmed as neoplastic tissue and excluded from
the analysis.
DNA was extracted by digestion with proteinase K (150mgml
 1
at 601C for 30min) in lysis buffer (10mM Tris-HCl pH 7.6, 5mM
EDTA, 150mM NaCl, 1% SDS), followed by DNA purification,
phenol and phenol–chloroform–isoamyl alcohol (25:24:1) ex-
traction and ethanol precipitation in 0.3 M sodium acetate (pH 4.6).
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oligoprimers targeting a fragment of the exon 7 within the TP53
gene, and DNA quantity analysis, evaluated by spectrophotometric
measurements, rendered 86 cases and 63 controls suitable for the
HPV detection. Testing for HPV was carried out with general-
primer-mediated PCR using the following primer pairs: (a) MY09/
MY11 (Resnick et al, 1990) and (b) GP5þ/GP6þ (de Roda
Husman et al, 1995), which preferentially amplify mucosal HPVs;
(c) CP65/CP70 followed by CP66/CP69 for the amplification of EV-
related HPV types (Berkhout et al, 1995); (d) FAP59/FAP64 for the
amplification of 75 different types of mucosal, cutaneous and EV-
related HPVs (Forslund et al, 1999). In addition, we used type-
specific PCR targeting E6 genes of individual HPV16 and HPV38
types (Tornesello et al, 2000; Caldeira et al, 2003). Serial dilution
(from one to 1000 copies) of 11 plasmid clones, containing
HPV genomes representative of mucosal (HPV6, 11, 16, 18, 31, 33),
cutaneous (HPV10), mucocutaneous (HPV2) and EV-related
(HPV5, 8, 38) HPV types, were used as positive controls.
Reaction mixtures without template DNA, included in every set
of five clinical specimens, represented the negative controls. All
amplified DNAs have been subjected to direct nucleotide sequence
analysis following procedures previously described (Tornesello
et al, 2000).
The data were analysed using w
2 test and, where appropriate,
Fisher’s exact test to calculate all P-values related to the differences
between groups with Epi Info 6 Statistical Analysis System
Software (6.04b, 1997, Centers for Disease Control and Prevention,
USA). Differences were considered to be statistically significant
when P-values were less than 0.05.
Table 1 Distribution of known variables between conjunctival neoplasia
cases and controls
Conjunctival
neoplasia n 86
(%)
Controls
a n 63
(%) P value
Sex 0.924
M 35 (40.7) 27 (42.8)
F 51 (59.3) 36 (57.1)
Age 0.955
r30 years 39 (45.3) 28 (44.7)
430 years 47 (54.6) 35 (55.3)
HPV PCR 0.002
Positive 17 (19.8) 1 (1.6)
Negative 69 (80.2) 62 (98.4)
HIV serology
b 0.01
Positive 56 (65.1) 15 (38.5)
Negative 30 (34.9) 24 (61.5)
HIV status Conjunctival
neoplasia n 86
(%)
Controls
a n3 9
b
(%)
P value
HIV positive 0.031
c
HPV-Pos 14 (25.0) 0 (0.0)
HPV-Neg 42 (75.0) 15 (100)
HIV negative 0.620
c
HPV-Pos 3 (10.0) 1 (4.2)
HPV-Neg 27 (90.0) 23 (95.8)
aTwo Pinguecula, one pterygium and one papilloma of the conjunctiva were included
in the control group.
bA total of 24 control subjects with undetermined HIV serology
were not included.
cFisher exact test, two-tailed.
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This study enrolled 125 cases with clinical presentations compa-
tible with conjunctival neoplastic lesions and 125 control subjects.
Following histological typing and DNA quality/quantity assays, 86
confirmed conjunctival neoplasia and 63 cancer-free control
samples were included in the HPV screening. Table 1 summarises
the selected characteristics of the subjects. There were no
significant differences between cases and controls in the distribu-
tion of age and sex, suggesting that the frequency matching on
these two variables were adequate. The median age was 32 years
(mean 34.5711.5 years) for the cases, and 30 years (mean
35.6710.7 years) for the controls. The HIV seroprevalence among
cases was significantly higher (P¼0.0095) than that observed in
controls, confirming that HIV infection is a relevant risk factor in
the pathogenesis of conjunctival carcinoma in this population
(Table 1).
All 86 cases and 63 controls have been analysed by PCR using
six primer sets to amplify mucosal, cutaneous as well as EV-related
HPV types. Combining the results obtained with MY09/MY11,
GP5þ/GP6þ, CP65/CP70-CP66/CP69 and HPV38 primer pairs,
18 samples were positive for the presence of HPVs (Table 1). No
viral sequences were detected in either cases or control with
FAP59/FAP64 and HPV16-specific primer pairs.
The HPV-positive samples comprise 17 (19.8%) conjunctival
neoplasia and one (1.6%) control biopsy (P¼0.0019). A total of 14
samples (25.0%), among the 56 conjunctival neoplasia from HIV-
positive subjects, tested positive for HPV sequences (P¼0.0312).
Only 10% (three out of 30) of the neoplastic samples, from HIV-
negative subjects, were HPV positive.
The histology of the 86 conjunctival neoplasia patients identified
29 (33.7%) lesions as ICSCC, 23 (26.7%) as CIN3, 18 (20.9%) as
CIN2 and 16 (18.6%) as CIN1. The HPV distribution among cases,
grouped by histological types, also stratified by HIV serology, are
summarised in Table 2. The frequency of HPV infection among
HIV-positive patients was 15% (three out of 20) in the ICSCC, 25%
(three out of 12) in CIN3, 36.3% (four out of 11) in CIN2 and
33.3% (four out of 12) in CIN1. HPV sequences among HIV-
negative patients were identified in 28.5% (two out of seven) of
CIN2, 25.5% (one out of four) of CIN1, 4.1% (one out of 23) of
controls and in none of the ICSCC and CIN3 samples. Therefore,
HPV detection frequency decreased in more advanced disease
stages.
Characterisation of the amplified HPV sequences allowed the
identification of two mucosal HPVs (6 and 18 types) and six EV-
related HPVs (14b, 20, 38, DL473, PPHL1FR and HPV100). A
putative new HPV sequence (CJ198) was identified in one ICSCC
and in one CIN1 sample.
DISCUSSION
Overall, this study suggests that mucosal and EV HPVs do infect
the conjunctival epithelium, but does not confirm a role for
specific HPVs in the development of conjunctival carcinoma.
Furthermore, the low frequency of EV HPV types in ICSCC
compared to that found in preneoplastic lesions (CIN1-2) suggests
that these HPV types are not involved in tumour progression.
These results are concordant with several others epidemiological
studies, performed by broad consensus PCRs, clearly indicating
that EV HPV types are commonly found in skin lesions (up to
90%) from immunosuppressed renal transplant recipients.
The high detection rates of HPV DNA both in healthy
skin biopsies, plucked hairs or skin swab samples in immuno-
competent (25–65% HPV-positivity) and in immunosuppressed
(30–90% positivity) individuals may suggest an ubiquity nature
of these viruses. Forslund et al (2004), analysing swab
samples collected on the top of skin tumours, found HPV DNA
in 69% of the samples against a 12% HPV positivity within the
biopsies of the same tumours; they concluded that HPV positivity
in skin tumour biopsies may merely reflect surface contamination
by viral DNA or particles harboured in cells shed from infected
healthy skin.
In conclusion, we report that in our study on conjunctival
neoplasia from sub-Sahara region, cutaneous HPVs were not
detected while mucosotropic HPV types have been rarely found.
Moreover, EV-related HPVs were frequently identified in low-
grade conjunctival neoplasia of HIV-positive patients but less
commonly in invasive conjunctival carcinomas. Thus, HPV DNA
found in conjunctival lesions might merely be a passenger.
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